health
The mysterious case of Eli Lilly’s obesity drug
Why this matters: health reporting relevant to everyday decisions and well-being.
Who got exclusive access to Eli Lilly’s highly anticipated obesity candidate? Why are drugmakers spending so much money on acquisitions? And are hair loss drugs a good investment? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. We bring on our colleague Lizzy Lawrence to discuss her scoop that Lilly and the Food and Drug Administration have allowed one person to receive the pharma company’s obesity candidate, retatrutide, through the FDA’s “compassionate use” program.Read the rest…
Article preview — originally published by STAT News. Full story at the source.
Read full story on STAT News →
More top stories
Also covered by
Aggregated and edited by the Scoop newsroom. We surface news from STAT News alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop